NPPA fixes price caps for 12 anti-diabetic medicines

NPPA fixed the ceiling prices for 12 anti-diabetic generic medicines, including glimepiride tablets, glucose injection and intermediate acting insulin solution.

October 25, 2021 11:03 pm | Updated 11:03 pm IST - New Delhi

Drug price regulator National Pharmaceutical Pricing Authority (NPPA) on Monday said it has fixed the ceiling prices for 12 anti-diabetic generic medicines, including glimepiride tablets, glucose injection and intermediate acting insulin solution.

In a tweet, the drug price regulator said, “To make it possible for every Indian to afford medical treatment against diseases like diabetes, NPPA has initiated a successful step by fixing the ceiling prices of 12 anti-diabetic generic medicines.” These include glimepiride tablet of strength 1 mg, with ceiling price at ₹3.6 per tablet, while that for 2 mg is ₹5.72 per tablet.

The ceiling price of 1 ml glucose injection of 25% strength has been fixed at 17 paise, while that of 1ml of insulin (soluble) injection of strength 40IU/ml is ₹15.09.

Similarly, 1 ml of intermediate acting (NPH) solution insulin injection of strength 40 IU/ml has a ceiling price of ₹15.09, and that of 1 ml of premix insulin 30:70 injection (regular NPH) injection of strength 40 IU/ml is also ₹15.09.

NPPA further said the ceiling price of metformin immediate release tablet of strength 500 mg has been fixed at ₹1.51 per tablet, while that of 750 mg strength is at ₹3.05 per tablet and 1,000 mg strength at ₹3.61 per tablet.

For metformin control release tablet of strength 1000 mg, the ceiling price is ₹3.66 per tablet, NPPA said, adding the same for 750 mg strength is ₹2.4 per tablet and ₹1.92 per tablet for metformin control release tablet of strength 500 mg.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.